Please assess the completion status of the following clinical trial:

Trial Title: Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section 3.2.1 for excluded subtypes)~* At least 3 sites of disease~  1. One for diagnosis (lymph node or bone marrow biopsy)~ 2. One palpable for treatment~ 3. One measurable radiographically~* \> 60 days after RIC allogeneic transplant for lymphoma~* 18 years of age or older~* Mixed (5-95%) or complete (\>95%) chimerism~* Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2~* ANC \>1000/mm3, platelets \>50,000/mm3~* Total bilirubin ≤ 2.5 mg/dL, AST and ALT \< 3 times upper limit of normal~* Serum creatinine ≤ 3 mg/dL~* No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatment~* Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤ 200 mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to scheduled treatment~Exclusion Criteria:~* HIV associated lymphoma~* Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)~* Active infection within 14 days prior to scheduled treatment~* Active Cytomegalovirus (CMV) disease at the time of enrollment~* Pre-existing autoimmune or antibody mediated disease (including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and autoimmune thrombocytopenia)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SD-101 + Combined with Local Radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).